The process of corneal wound closure is a complex and not entirely understood phenomenon, which includes apoptosis, cell migration, proliferation, differentiation, and restructuring of the extracellular matrix. Communication between the epithelium and the stroma is of great importance for these events to proceed in the correct way and this communication involves both the secretion of soluble proteins and the release of extracellular vesicles (EVs) carrying specific signaling molecules. EVs are lipid bilayer structures released by virtually all cell types, serving as important mediators in intercellular communication. The cargo can be a diverse array of macromolecules, including proteins, RNA, and DNA, with their composition being intricately regulated by the cellular source and for the intended recipient. EVs have been proposed as potential therapeutic agents in various corneal diseases such as glaucoma, dry eye disease and corneal scarring. In our earlier work on cell-free implants in pigs, we observed that EVs were released from the regenerating epithelium. These observations led us to believe that these EVs play a role in corneal epithelial wound healing and stromal regeneration. This is supported by other studies which demonstrated that mouse corneal epithelial cell-derived EVs mediate the cell-cell communication between corneal epithelial cells, keratocytes, and endothelial cells, indicating the potential role of corneal epithelial EVs (CE-EVS) in corneal regeneration. They also demonstrated that these EVs fuse with keratocytes in vitro to induce myofibroblast differentiation, which plays a crucial role in the process of wound closure. This was further studied by McKay et al. which demonstrated that EVs originating from immortalized human corneal epithelial cells promote the differentiation of fibroblasts into myofibroblasts. More recently, Desjardins et al. isolated EVs from primary corneal epithelial cells, corneal endothelial cells, and corneal fibroblast and demonstrated that the process of corneal epithelial wound healing was accelerated by the addition of all types of corneal EVs, but particularly by corneal epithelial EVs (CE-EVs). Nonetheless, to achieve complete healing often multiple doses of EVs were needed, which emphasizes one major drawback associated with administrating EVs. When administered alone they exhibit a short half-life and are rapidly cleared from the body. For administration in the eye, the tear film is replaced every 5 minutes under normal conditions, and in the case of topical application of drugs the tear secretion is increased. Hence, the concern is that EVs will be quickly washed away through the nasolacrimal duct leading to low bioavailability. To address this issue, it has been proposed to utilize delivery scaffolds from which EVs can be released sustainably. Nonetheless, so far there are no reports of EVs being sustainably delivered to the eye. We hypothesized that a sustained release of EVs from a pre-fabricated corneal implant or an adhesive biodegradable corneal sealant could be of great importance for corneal regeneration in case of keratoplasty with a corneal implant, and during repairing corneal perforations or in situ molding of corneal defects in a sutureless keratoplasty. We previously developed a loadable, chemically crosslinked adhesive hydrogel with adhesion strength comparable to fibrin glue, suitable for repairing corneal perforations and in situ molding of corneal defects in its as-prepared state. Additionally, when fully cured, these hydrogels hold potential as prefabricated corneal implants for use in keratoplasty.